Department of Neurology, Division of Clinical Neuroscience, University of Calgary, Calgary, Alta., Canada. aganesh @ ucalgary.ca
Eur Neurol. 2013;70(1-2):48-58. doi: 10.1159/000348780. Epub 2013 May 23.
Since 2009, the (CCSVI) model of multiple sclerosis has drawn much attention, and the associated surgical 'venoplasty' interventions have often been advertised as a novel idea. In fact, it is a new incarnation of various vessel-based therapies attempted for multiple sclerosis in the past, dating back to the 1930s, when Tracy Jackson Putnam (1894-1975) attempted pharmacological anticoagulation. This was followed in the 1940s by Richard M. Brickner's (1896-1959) studies of vasodilatory drugs, which further inspired trials of sympathectomy and ganglionectomy. In the 1950s, Ilya Mark Scheinker (1902-1954) studied vasopressor therapy, while Roy Laver Swank (1909-2008) investigated the effects of a low saturated fat diet in his patients. This paper discusses the longer history of these therapeutic endeavours and the aetiological theories that inspired them.
自 2009 年以来，多发性硬化症的（CCSVI）模型引起了广泛关注，相关的手术“静脉成形术”干预措施经常被宣传为一种新的理念。事实上，这是过去针对多发性硬化症尝试的各种基于血管的治疗方法的新体现，可以追溯到 20 世纪 30 年代，当时 Tracy Jackson Putnam（1894-1975）尝试了药物抗凝。随后在 20 世纪 40 年代，Richard M. Brickner（1896-1959）研究了血管扩张药物，这进一步激发了交感神经切除术和神经节切除术的试验。在 20 世纪 50 年代，Ilya Mark Scheinker（1902-1954）研究了升压治疗，而 Roy Laver Swank（1909-2008）则在他的患者中研究了低饱和脂肪饮食的影响。本文讨论了这些治疗努力的更长历史以及激发它们的病因理论。
